June 2, 2021

Emerging SARS-CoV-2 Variants of Concern Evade Humoral Immune Responses from Infection and Vaccination

Category: Article Summary

Topic: Vaccines and Immunity

Keywords (Tags): immunity, variants

• [Pre-print, not peer-reviewed] Anti-SARS-CoV-2 antibody binding and neutralizing activity in sera of both convalescent individuals who had recovered from infection that occurred prior to the spread of variants of concern (VOC) (n=69) and recipients of the Pfizer-BioNTech vaccine (n=50) were reduced against the B.1.1.7, B.1.351, and P.1 VOC, according to a cohort study. The largest reductions in neutralization were up to 4- to 7-fold by the B.1351 variant. While hospitalized COVID-19 patients and vaccinated individuals produced sufficient neutralizing activity against all variants, nearly 4 in 10 non-hospitalized patients did not neutralize B.1.351. Binding activity of monoclonal antibody treatments targeting the receptor binding domain were substantially reduced against B.1.351, but not against B.1.1.7.

Caniels et al. (June 1, 2021). Emerging SARS-CoV-2 Variants of Concern Evade Humoral Immune Responses from Infection and Vaccination. Pre-print downloaded Jun 2 from https://doi.org/10.1101/2021.05.26.21257441